[Ranolazine--new treatment of chronic stable angina pectoris].
Ranolazine sustained-release tablets were recently approved in the EU for chronic stable angina as add-on therapy when symptoms are not controlled with first-line agents. The mechanism of action is thought to involve inhibition of late sodium influx in the heart, which can reduce abnormalities of contractility and repolarisation associated with ischaemia. Ranolazine increases the exercise capacity, reduces angina, and diminishes the use of nitroglycerine. The drug has an excellent safety profile and may be a valuable addition to the treatment of chronic stable angina.
Ahlehoff
Ole
O
Kardiologisk Afdeling P, Gentofte Hospital, DK-2900 Hellerup, Denmark.
Hansen
Peter Riis
PR
D000083:Acetanilides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069458:Ranolazine; D016896:Treatment Outcome
D000083:Acetanilides; D003692:Delayed-Action Preparations; D004791:Enzyme Inhibitors; D010879:Piperazines; D000069458:Ranolazine